Trump Executive Order Tracker | Akin Public Policy and Lobbying

Regulatory Relief to Promote Domestic Production of Critical Medicines (Trump EO Tracker)

May 5, 2025

Reading Time : 1 min
Trump Executive Order Tracker | Akin Public Policy and Lobbying

This order streamlines the regulation of manufacturing pharmaceutical products and inputs to facilitate the restoration of a robust domestic pharmaceutical manufacturing base.

Within 180 days, the order directs the Secretary of Health and Human Services, through the FDA Commissioner, to review existing regulations and guidance that pertain to the development of domestic pharmaceutical manufacturing and take steps to eliminate any duplicative or unnecessary requirements in such regulations and guidance; maximize the timeliness and predictability of agency review; and streamline and accelerate the development of domestic pharmaceutical manufacturing.

Within 90 days of the order, the FDA Commissioner is directed to develop and advance improvements to the risk-based inspection regime that ensures routine reviews of overseas manufacturing facilities involved in the supply of United States medicines, funded by increased fees on foreign manufacturing facilities and the FDA Commissioner must publicly disclose the annual number of inspections that the FDA conducts on such foreign facilities.

Within 180 days, the order instructs the Administrator of the Environmental Protection Agency (EPA) to take action to update regulations and guidance that apply to the inspection and approval of new and expanded manufacturing capacity of pharmaceutical products, active pharmaceutical ingredients, key starting materials, and associated raw materials in the United States to eliminate any duplicative or unnecessary requirements and maximize the timeliness and predictability of agency review.

Within 180 days of the order, the Secretary of the Army, acting through the Assistant Secretary of the Army for Civil Works, shall review the nationwide permits issued under section 404 of the Clean Water Act of 1972 (33 U.S.C. 1344) and section 10 of the Rivers and Harbors Appropriation Act of 1899 (33 U.S.C. 403) to determine whether an activity-specific nationwide permit is needed to facilitate the efficient permitting of pharmaceutical manufacturing facilities.

Additional Documentation

Share This Insight

Related Content

Trump Executive Order Tracker

The significant number of executive orders published by the Trump Administration cut across dozens of industries and areas of law. This searchable tool breaks down the orders and their impacts on specific industries and with in-depth analysis of specific orders.

Previous Entries

Trump Executive Order Tracker

May 5, 2025

This Executive Order establishes a policy of the United States to ensure that federally funded research benefits American citizens without jeopardizing national security, strength or prosperity. The order seeks to strengthen oversight of dangerous gain-of-function research on biological agents and pathogens and other high-risk life science research. It contains the following directives and deadlines.

...

Read More

Trump Executive Order Tracker

May 2, 2025

Instructs the Corporation for Public Broadcasting (CPB) Board of Directors and all executive departments and agencies to cease Federal funding for National Public Radio (NPR) and the Public Broadcasting Service (PBS).

...

Read More

Trump Executive Order Tracker

May 1, 2025

Establishes Religious Liberty Commission (Commission) with the stated intent of protecting the free exercise of religion.

...

Read More

Trump Executive Order Tracker

April 28, 2025

Enforces the English-language requirement for commercial motor vehicle drivers and removing regulatory burdens that undermine the working conditions of America’s truck drivers.

...

Read More

Trump Executive Order Tracker

April 28, 2025

Orders the Attorney General to publish a list of States and local jurisdictions that obstruct the enforcement of Federal immigration laws (sanctuary jurisdictions). Immediately following each publication, the Attorney General and the Secretary of Homeland Security shall notify each sanctuary jurisdiction regarding its defiance of Federal immigration law enforcement and any potential violations of Federal criminal law. They will then pursue all necessary legal remedies and enforcement measures to end these violations and bring such jurisdictions into compliance with the laws of the United States.

...

Read More

Trump Executive Order Tracker

April 28, 2025

Orders the Attorney General shall take all appropriate action to create a mechanism to provide legal resources and indemnification to law enforcement officers who unjustly incur expenses and liabilities for actions taken during the performance of their official duties to enforce the law.  This mechanism shall include the use of private-sector pro bono assistance for such law enforcement officers.

...

Read More

Trump Executive Order Tracker

April 24, 2025

The Order institutes a new Civil Service Rule XI to ensure agencies effectively utilize probationary and trial periods. Civil Service Rule XI supersedes subpart H and requires agencies to affirmatively determine that the continued employment of individuals serving probationary or trial periods would benefit the federal service before the appointment is finalized. Civil Service Rule II is amended by removing section 2.4 of part 2 of title 5, Code of Federal Regulations. The rule determines the meaning of a probationary and trial period and sets guidance for assessment at the end of the trial or probationary period. At the completion of the period, the employee will either be terminated from their agency or certified as an appointment that advances public interest. The Order is effective immediately, and the requirements will become effective 90 days from April 24, 2025. 

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.